alexa Meal-Induced Oxidative Stress | Open Access Journals
ISSN: 2161-1017
Endocrinology & Metabolic Syndrome
Like us on:
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Meal-Induced Oxidative Stress

Ngoc-Anh Le*

Biomarker Core Laboratory, Atlanta Research and Education Foundation, Atlanta Veterans Affairs Medical Center, Georgia, USA

Corresponding Author:
Ngoc-Anh Le
Biomarker Core Laboratory
Atlanta Research and Education Foundation
Atlanta Veterans Affairs Medical Center, Georgia, USA
Tel: + 404-728-7632
E-mail: [email protected]

Received Date: August 04, 2016; Accepted Date: January 20, 2017; Published Date: February 20, 2017

Citation: Le NA (2017) Meal-Induced Oxidative Stress . Endocrinol Metab Syndr 6:258. doi:10.4172/2161-1017.1000258

Copyright: © 2017 Ngoc-Anh Le, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Endocrinology & Metabolic Syndrome

Abstract

The target of interventions to reduce cardiovascular events has focused on total (CHOL) and low-density (LDLC) cholesterol levels. Data from the Framingham Heart Study would suggest that 50% of individuals with so-called “normal” LDLC levels (100 mg/dl or 2.6 mmol/L) would have atherosclerosis by age 50 [1].

Short Communication

The target of interventions to reduce cardiovascular events has focused on total (CHOL) and low-density (LDLC) cholesterol levels. Data from the Framingham Heart Study would suggest that 50% of individuals with so-called “normal” LDLC levels (100 mg/dl or 2.6 mmol/L) would have atherosclerosis by age 50 [1]. In the Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE-IT), aggressive cholesterol reduction as part of a secondary trial in highrisk patients only prevented 20% of cardiac events [2]. Bayturan et al reported that, even when aggressive treatment was used to lower mean LDLC to 58.4 mg/dl (1.5 mmol/L), plaque volume could be shown to increase in 20% of the subjects [3]. Attempts to explain this residual risk have ranged from triglycerides (TG), high-density lipoprotein cholesterol (HDLC) [4] to non-HDLC [5] and biomarkers of inflammatory stress [6].

More recently, the concept of functional assays has been suggested as a novel perspective on risk factors beyond concentrations. While elevated HDL is commonly associated with lower CHD risk in both men and women [7], there is better understanding of the impact of HDL heterogeneity on its quantity, quality and function [8]. While one of the key anti-atherogenic properties of HDL is its ability to protect LDL from oxidative modification, in certain metabolic conditions, HDL may actually act as a pro-oxidant and pro-inflammatory agent [9,10]. HDL also plays a central role in cholesterol efflux, however, this functional parameter as measured ex vivo does seem to depend solely on HDLC and apoA-I levels [11].

With respect to LDL, the process is much more complicated. It is generally accepted that LDL in its native form is not atherogenic. LDL must undergo oxidative modification for the undesirable accumulation in the cells to start via the scavenger receptors [12,13]. According to the oxidation hypothesis of atherosclerosis, LDL must be trapped in the subendothelium for the oxidative modification to take place [14]. An alternative process which allows for the direct generation of oxidative epitopes in the circulation [15,16] could be proposed based on the postprandial hypothesis of atherosclerosis of Zilversmit [17]. In this scheme, as triglyceride-rich lipoproteins (TRL) interact with lipoprotein lipase anchored on the arterial wall they would be seeded with reactive oxygen species generated by an inflamed endothelium [18-20]. As the TRL are being converted to cholesterol-rich lipoproteins, either chylomicron remnants or LDL, the oxidative modification can either proceed to generate damaged lipoprotein particles or be quenched by an adequate antioxidant environment. In dyslipidemic conditions, e.g. metabolic syndrome and diabetes mellitus, the delayed clearance of triglycerides would facilitate the completion of the oxidative modification process.

In a recent double-blind, placebo-controlled, cross-over metabolic study with fenofibric acid (ABT-335), we examined the hypothesis that oxidative modification of LDL could be reduced by improving triglyceride hydrolysis in the fasting and postprandial state [21]. In this study, patients with metabolic syndrome were followed for two 8-week treatment periods separated by a 4-week washout period. During the first treatment period, participants were randomly assigned to ABT-335 or placebo and the treatment was switched for the second period. At the end of each treatment period, participants were admitted to the metabolic ward for a 6-hr meal challenge study. The meal challenge consisted of a standardized mixed meal that included only a modest amount of fat (27 g). Plasma obtained at baseline and at 4 hour postprandial were used to isolate the lipoprotein-rich fraction (d<1.21 gm/m) by ultracentrifugation within 4 hours of collection. The isolated lipoprotein-rich fraction was stored at -80oC until the completion of the second meal challenge. There was the expected 20% reduction in plasma triglycerides (p<0.0002) with no change in LDLC. There was a 28% reduction in incremental area under the curve for triglycerides following the meal challenge (p<0.0005).

Autologous LDL and HDL were obtained from the lipoprotein-rich fraction by fast protein liquid chromatography and used to examine the oxidative susceptibility of LDL in the presence of Cu++. Of the 27 patients with metabolic syndrome, fasting LDL for 15 individuals underwent spontaneous auto-oxidation without requiring the addition of Cu++ as initiator. This was observed during both the placebo and the ABT-335 periods. LDL isolated from postprandial plasma underwent auto-oxidation in 17 subjects during the placebo period and in only 10 subjects during the ABT-335 period. Mean lag time for fasting LDL was 16% longer after treatment with ABT-335 than after treatment with placebo. This modest increase in resistance to oxidation with ABT-335 was not statistically significant in this small group of subjects. Mean lag time for postprandial LDL was 28% longer with ABT-335 than with placebo (p<0.015). This finding suggests that ABT-335 enhanced the clearance of postprandial triglycerides resulting in greater resistance of postprandial LDL to Cu++-induced oxidative modification [21].

In the presence of Cu++, co-incubation with autologous HDL obtained either from fasting or postprandial plasma actually reduced the lag time for LDL. This is the case for both the placebo and ABT-335 period, suggesting that these patients with metabolic syndrome may have dysfunctional HDL and ABT-335 did not restore the anti-oxidant properties of HDL [21].

In summary, to fully appreciate the pro-and/or anti-atherogenic of lipid and lipoprotein biomarkers, we might need to develop clinically relevant functional assays rather than simply focusing on plasma concentrations [11,22]. With respect to oxidative modification, we need to appreciate that certain properties of plasma lipoproteins might not be conserved during postprandial lipemia especially in view of the strong evidence that meal consumption is associated with oxidative and inflammatory stress [22-25].

References

Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Recommended Conferences

Article Usage

  • Total views: 439
  • [From(publication date):
    February-2017 - Sep 23, 2017]
  • Breakdown by view type
  • HTML page views : 381
  • PDF downloads :58
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords